Loredana La Mantia

Learn More
OBJECTIVES Health related quality of life (HRQOL) inventories are multi-dimensional measures of patient-centred health status developed for clinical research. The MS quality of life 54 (MSQOL-54) is an MS-specific HRQOL inventory originally devised for English speaking patients. It consists of a core measure, the 36-item short form health survey (SF-36)(More)
Forty patients, affected by multiple sclerosis with remitting-relapsing or progressive course, were included in a double blind study of treatment with azathioprine (2 mg/kg/day) lasting 3 years. The mean changes on the Expanded Disability Status Scale and in the survival analysis show a trend in favour of azathioprine both in slowing disease progression and(More)
Headache is not generally considered as a symptom of multiple sclerosis (MS), but several studies have showed that it is more frequent (about 50%) in MS patients than in controls or general population. Headache may occur at onset and during the course of the disease. Tension-type headache and migraine without aura are the most commonly reported primary(More)
The preliminary results of a post-marketing study on relapsing-remitting multiple sclerosis patients treated with immunomodulating agents attending the Lombardia Region’s Multiple Sclerosis Centers are presented. A total of 294 patients treated with Betaferon (67), Avonex (115), Rebif 22 (45), Rebif 44 (18) and Copaxone (49) were included. Relapse frequency(More)
Ten patients with multiple sclerosis and treated with interferon-β1b (IFN-β1b) were followed-up for 1 year with quantitation of serum VCAM-1 and ICAM-1 levels, mean fluorescence intensity of HLA-DR, VLA-4, CD11a, and CD18 on peripheral blood monocytes and lymphocytes, and adhesion of peripheral blood monocytes and CD45+ cells on endothelial cell monolayers.(More)
The aim of the study was to evaluate the efficacy of interferon beta-1a (IFN-β-1a) and beta-1b (IFN-β-1b) in clinical practice for the treatment of relapsing-remitting multiple sclerosis (RR MS). Patients were selected and prospectively monitored according to a predefined protocol. An appropiate form was prepared to collect clinical data of multiple(More)
Azathioprine (Aza) has been proposed in the treatment of multiple sclerosis (MS) since 1971 and continues to be used in MS Clinical Centres. Recent data, suggesting its efficacy in reducing MRI lesion load and in refractory IFN-treated MS patients, has renewed interest in this drug. Its therapeutic index over other immunosuppressive agents is generally(More)
Sir: The relationship between emotional stress and multiple sclerosis (MS) has been addressed in a number of studies, the majority of which have dealt with the occurrence of relapses in the course of already diagnosed disease [ 1-4]. The results of these studies have been conflicting due to differences in methodology (i.e. selection of control groups and(More)
Previous reports have suggested an increased risk of psoriasis in MS patients. Worsening of dermatologic lesions during interferon therapy has been rarely reported, but activation of psoriatic arthritis has not been described until now. The following is a case report. A 37-year-old woman affected by relapsing–remitting multiple sclerosis had severe(More)
The effect of the opiate antagonist naloxone was evaluated in 11 unselected patients with cerebral ischemia. Naloxone reversed neurological deficits in the 4 patients with less evident signs of vascular damage. L'effetto del Naloxone, antagonista degli oppiacei, è stato valutato in 11 pazienti affetti da ischemia cerebrale. Il Naloxone ha fatto regredire i(More)